Johnson & Johnson Buys New Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Johnson & Johnson acquired a new stake in Neumora Therapeutics, Inc. (NASDAQ:NMRAFree Report) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 912,128 shares of the company’s stock, valued at approximately $12,870,000. Neumora Therapeutics makes up 4.7% of Johnson & Johnson’s investment portfolio, making the stock its 6th largest holding. Johnson & Johnson owned approximately 0.60% of Neumora Therapeutics at the end of the most recent reporting period.

Separately, Citigroup Inc. acquired a new position in shares of Neumora Therapeutics in the third quarter valued at approximately $203,000.

Insider Transactions at Neumora Therapeutics

In other news, major shareholder Arch Venture Partners Xii, Llc purchased 3,357 shares of the firm’s stock in a transaction on Tuesday, November 14th. The stock was bought at an average cost of $11.98 per share, for a total transaction of $40,216.86. Following the completion of the acquisition, the insider now directly owns 4,131,207 shares of the company’s stock, valued at $49,491,859.86. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Neumora Therapeutics Trading Down 2.0 %

Shares of NASDAQ NMRA traded down $0.36 during mid-day trading on Monday, reaching $18.06. The company had a trading volume of 225,817 shares, compared to its average volume of 196,911. Neumora Therapeutics, Inc. has a twelve month low of $9.35 and a twelve month high of $19.30. The stock has a 50 day simple moving average of $15.23.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Deutsche Bank Aktiengesellschaft initiated coverage on Neumora Therapeutics in a research note on Tuesday, December 12th. They issued a “hold” rating and a $13.00 price target on the stock. JPMorgan Chase & Co. lowered their target price on Neumora Therapeutics from $21.00 to $20.00 and set an “overweight” rating for the company in a report on Wednesday, November 8th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $21.29.

Check Out Our Latest Stock Analysis on NMRA

Neumora Therapeutics Profile

(Free Report)

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.

Further Reading

Want to see what other hedge funds are holding NMRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neumora Therapeutics, Inc. (NASDAQ:NMRAFree Report).

Institutional Ownership by Quarter for Neumora Therapeutics (NASDAQ:NMRA)

Receive News & Ratings for Neumora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neumora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.